Bill Kelly
Founder and Managing Director
Strategic CFO and life sciences finance leader with 25+ years of experience guiding healthcare companies from development through commercialization to successful IPO, strategic exit, and long-term value creation—bringing disciplined financial leadership to scale organizations, navigate complex inflection points, and support capital formation.
Experience and Track Record
Bill Kelly is a seasoned financial executive with more than 25 years of experience helping high-growth life sciences, diagnostics, medical device, and healthcare technology companies navigate from development through commercialization to financing, strategic exit, and long-term value creation. Over the course of his career, he has built and led finance organizations, raised significant growth capital, guided public and private companies through transformational milestones, and partnered closely with founders, boards, and investors to create substantial shareholder value.
Most recently, Bill served as Chief Financial Officer of SpectraWAVE, where he helped lead the company through its acquisition by Philips. During his tenure, the company achieved four FDA clearances, supporting its transition toward commercial scale. The outcome represented nearly a 3.5x multiple from the company’s last financing round in approximately one year and reflected the strategic and financial value created through disciplined execution, strong investor alignment, and effective transaction leadership.
Prior to SpectraWAVE, Bill served as Chief Financial Officer of Vicarious Surgical, where he led the company through its September 2021 public listing at an approximate $1.1 billion valuation—nearly a 10x increase from the prior venture financing round—and helped raise more than $275 million across the initial and follow-on offerings, further reinforcing his track record of delivering significant step-ups in enterprise value. He built the company’s public-company finance infrastructure, established investor relations and FP&A capabilities, managed key banking and audit relationships, and helped position the business to fund operations through its next phase of clinical and regulatory development.
Earlier, Bill was Chief Financial Officer and Corporate Secretary of Exosome Diagnostics, where he helped guide the company from development stage through commercial launch and multiple financing rounds totaling nearly $60 million, culminating in a successful $575 million acquisition by Bio-Techne. During his tenure, the company launched a novel diagnostics platform spanning prostate, lung, and bladder cancer applications, secured broad reimbursement coverage, and expanded rapidly as it moved into commercial operations.
Bill also served as Chief Financial Officer of Repligen Corporation, where he helped lead a strategic pivot that transformed the company from a development-stage therapeutics business into a high-growth bioprocessing platform. The repositioning—executed in the public markets through disciplined capital allocation and strategic acquisitions—ultimately drove significant long-term shareholder value. Earlier in his career, he held senior finance leadership positions at Haemonetics, Deloitte, and Ernst & Young.
At Spinnaker Strategic Finance, Bill brings deep experience in strategic finance, transaction execution, commercialization planning, investor communications, governance, and operational scaling, with a strong track record of supporting capital formation. His background is particularly valuable to companies developing novel diagnostic and medical technologies that require disciplined financial leadership, thoughtful growth planning, and strong execution across complex strategic milestones.